Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 3/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | EIF4E | P06730 | 2/20 | 0.32 |
| ▸ | ECE1 | P42892 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 2/20 | 0.31 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16237675 | 0.89 | ADORA2A (0.39) | CTSAHCRTR1HCRTR2ADORA2ARORC | |
| SCHEMBL16237698 | 0.88 | ADORA2A (0.33) | CTSAADORA2AEIF4EECE1HDAC3 | |
| SCHEMBL17064250 | 0.88 | HCRTR1 (0.39) | CTSAHCRTR1HCRTR2ADORA2AECE1 | |
| SCHEMBL17064231 | 0.86 | KMT2A (0.40) | CTSAADORA2AECE1HDAC3HDAC1 | |
| SCHEMBL18074580 | 0.85 | CTSA (0.41) | CTSAHCRTR1HCRTR2ADORA2ATYK2 | |
| SCHEMBL17064234 | 0.83 | NPC1 (0.37) | CTSAADORA2AEIF4EDHODH | |
| SCHEMBL16236743 | 0.83 | ADORA2A (0.39) | ADORA2AECE1PTGDR2HDAC3HDAC1 | |
| SCHEMBL16237487 | 0.82 | HDAC3 (0.43) | ADORA2AEIF4EHDAC3HDAC1HDAC6 | |
| SCHEMBL16237062 | 0.82 | ECE1 (0.34) | CTSAHCRTR1HCRTR2ADORA2AEIF4E | |
| SCHEMBL16237622 | 0.80 | KMO (0.41) | ADORA2ARORCEIF4ETRPM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3270915-A1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | F. Hoffmann-La Roche AG (CH) | 2018-01-24 | — | — | EP | disclosed |
| EP-3114128-A1 | NOVEL 6-FUSED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2017-01-11 | — | — | EP | disclosed |
| WO-2016146598-A1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-22 | — | — | WO | disclosed |
| EP-2997032-A1 | 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2016-03-23 | — | — | EP | disclosed |
| WO-2015132276-A1 | NOVEL 6-FUSED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2015-09-11 | — | — | WO | disclosed |
| WO-2014184328-A1 | 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-20 | — | — | WO | disclosed |